Astria Therapeutics, Inc.
ATXS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.36 | -0.08 | -1.06 | 0.00 |
| FCF Yield | -11.79% | -10.98% | -3.44% | -4.50% |
| EV / EBITDA | -6.68 | -7.04 | -15.21 | -18.84 |
| Quality | ||||
| ROIC | -13.50% | -12.57% | -9.12% | -8.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 1.09 | 1.01 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 890,333.66% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -7.73% | -95.93% | 37.96% | -63.69% |
| Safety | ||||
| Net Debt / EBITDA | 2.00 | 1.33 | 1.84 | 2.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |